Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioNTech SE
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Ramp-up is possible thanks to increased internal capacity and network of voluntary licensing partners including Mylan, Cipla and Dr Reddy's.
Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in selected regions, in another endorsement of the Indian group's capabilities. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India until the deal ends and non-exclusive rights for developing countries to the end of the pandemic, with the US firm getting half of net revenue.
The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- BioNTech US Inc.
- Biopharmaceutical New Technologies AG
- Neon Therapeutics, Inc.
- BioNTech AG